Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rasikh Tuktamyshov"'
Autor:
Borna Vajdi, Rasikh Tuktamyshov
Publikováno v:
World Journal of Cardiology
The aim of this study was to review the most recent literature on the safety of electronic cigarettes (ECs) in the context of cardiovascular disease and in the context as a tool for smoking cessation and recreational purposes. The format of this revi
Publikováno v:
World Journal of Cardiology
AIM To review the early and more recent studies of Bivalirudin, to assess the safety, effectiveness, and cost benefits of this drug. METHODS Literature search of MEDLINE and PubMed databases from 1990 to 2017 using keywords as "bivalirubin" and "angi
Autor:
Mehmet Altan, David L. Rimm, James W. Smithy, Kurt A. Schalper, Nikita Mani, Brad Wasserman, Yuting Liu, Maria I. Toki, Rasikh Tuktamyshov, Konstantinos N. Syrigos
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(12)
PURPOSE: PD-1/PD-L1 axis inhibitors have been proven effective, especially in patients with tumors expressing Programmed Death Ligand 1 (PD-L1). Their clinical efficacy in patients with epidermal growth factor receptor (EGFR) activating mutations is
Autor:
Renad Zhdanov, Rasikh Tuktamyshov
Publikováno v:
Hematology. 20:584-586
Coagulation is a cascade of reactions that eventually leads to formation of thrombin and fibrin. The two most frequently used tests to describe the coagulation system are activated partial thromboplastin time and international normalized ratio. Both
Autor:
Alice Chuan Li, Maria I. Toki, Miguel F. Sanmamed, Kurt A. Schalper, Roy S. Herbst, Lieping Chen, Franz Villarroel-Espindola, Ila Datar, David L. Rimm, Rasikh Tuktamyshov, Brian S. Henick, Konstantinos N. Syrigos, Jovian Yu
Publikováno v:
Journal of Clinical Oncology. 36:12002-12002
12002Background: Despite innate immunity’s prominent role in the anti-tumor response, little is known about the MC composition of human NSCLC. We used multiplexed quantitative immunofluorescence (Q...
Autor:
Mehmet Altan, Brad Wasserman, James W. Smithy, Nikita Mani, Rasikh Tuktamyshov, David L. Rimm, Yuting Liu, Maria I. Toki, Konstantinos N. Syrigos
Publikováno v:
Journal of Clinical Oncology. 35:9076-9076
9076 Background: PD-1/PD-L1 axis inhibitors have been proven effective, especially in patients expressing Programmed Death Ligand 1 (PD-L1). Their clinical efficacy in patients with epidermal growth factor receptor (EGFR) activating mutations is stil
Publikováno v:
BMC Research Notes
Background Merkel cell carcinoma is a rare and aggressive skin malignancy that arises from primary neural cells and has a tendency for local recurrence and regional lymph node metastases. There are only a few cases in the literature reporting metasta